IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v14y2013i4p629-638.html
   My bibliography  Save this article

Palliative treatment of colorectal cancer in Germany: cost of care and quality of life

Author

Listed:
  • Martin Emmert
  • Katharina Pohl-Dernick
  • Axel Wein
  • Frank Dörje
  • Susanne Merkel
  • Frank Boxberger
  • Gudrun Männlein
  • Robert Joost
  • Hans-Detlev Harich
  • Roland Thiemann
  • Christof Lamberti
  • Markus Neurath
  • Werner Hohenberger
  • Oliver Schöffski

Abstract

This is the first study assessing the costs of palliative care and the quality of life of patients with CRC in real-world health-care delivery in Germany. It could be shown that CRC treatment represents an enormous economic burden to the German health-care system. Increased efforts in promoting effective and efficient treatment options, or performance-based medication reimbursement schemes, might be helpful in reducing the costs. Copyright Springer-Verlag 2013

Suggested Citation

  • Martin Emmert & Katharina Pohl-Dernick & Axel Wein & Frank Dörje & Susanne Merkel & Frank Boxberger & Gudrun Männlein & Robert Joost & Hans-Detlev Harich & Roland Thiemann & Christof Lamberti & Markus, 2013. "Palliative treatment of colorectal cancer in Germany: cost of care and quality of life," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(4), pages 629-638, August.
    • Handle: RePEc:spr:eujhec:v:14:y:2013:i:4:p:629-638
    DOI: 10.1007/s10198-012-0408-5
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s10198-012-0408-5
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1007/s10198-012-0408-5?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Laurence Clerc & Valérie Jooste & Catherine Lejeune & Bernard Schmitt & Patrick Arveux & Catherine Quantin & Jean Faivre & Anne-Marie Bouvier, 2008. "Cost of care of colorectal cancers according to health care patterns and stage at diagnosis in France," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 9(4), pages 361-367, November.
    2. Nickel, Stefan & Thiedemann, Birgit & von dem Knesebeck, Olaf, 2010. "The effects of integrated inpatient health care on patient satisfaction and health-related quality of life: Results of a survey among heart disease patients in Germany," Health Policy, Elsevier, vol. 98(2-3), pages 156-163, December.
    3. L. Tilson & L. Sharp & C. Usher & C. Walsh & Whyte S & A. O’Ceilleachair & C. Stuart & B. Mehigan & M. John Kennedy & P. Tappenden & J. Chilcott & A. Staines & H. Comber & M. Barry, 2012. "Cost of care for colorectal cancer in Ireland: a health care payer perspective," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(4), pages 511-524, August.
    4. Carlson, Josh J. & Sullivan, Sean D. & Garrison, Louis P. & Neumann, Peter J. & Veenstra, David L., 2010. "Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers," Health Policy, Elsevier, vol. 96(3), pages 179-190, August.
    5. Catherine Lejeune & Christine Binquet & Franck Bonnetain & Amel Mahboubi & Michal Abrahamowicz & Thierry Moreau & Maria Raikou & Laurent Bedenne & Catherine Quantin & Claire Bonithon-Kopp, 2009. "Estimating the cost related to surveillance of colorectal cancer in a French population," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 10(4), pages 409-419, October.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Ulrike Haug & Susanne Engel & Frank Verheyen & Roland Linder, 2014. "Estimating Colorectal Cancer Treatment Costs: A Pragmatic Approach Exemplified by Health Insurance Data from Germany," PLOS ONE, Public Library of Science, vol. 9(2), pages 1-5, February.
    2. Pauline Chauvin & Jean-Michel Josselin & Denis Heresbach, 2014. "The influence of waiting times on cost-effectiveness: a case study of colorectal cancer mass screening," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(8), pages 801-812, November.
    3. Evgeni Dvortsin & Judith Gout-Zwart & Ernst-Lodewijk Marie Eijssen & Jan van Brussel & Maarten J Postma, 2016. "Comparative Cost-Effectiveness of Drugs in Early versus Late Stages of Cancer; Review of the Literature and a Case Study in Breast Cancer," PLOS ONE, Public Library of Science, vol. 11(1), pages 1-12, January.
    4. L. Tilson & L. Sharp & C. Usher & C. Walsh & Whyte S & A. O’Ceilleachair & C. Stuart & B. Mehigan & M. John Kennedy & P. Tappenden & J. Chilcott & A. Staines & H. Comber & M. Barry, 2012. "Cost of care for colorectal cancer in Ireland: a health care payer perspective," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(4), pages 511-524, August.
    5. Marcelien H. E. Callenbach & Rick A. Vreman & Aukje K. Mantel-Teeuwisse & Wim G. Goettsch, 2022. "When Reality Does Not Meet Expectations—Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital Drugs," IJERPH, MDPI, vol. 20(1), pages 1-12, December.
    6. Fernando Antonanzas & Carmelo Juárez-Castelló & Reyes Lorente & Roberto Rodríguez-Ibeas, 2019. "The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments," PharmacoEconomics, Springer, vol. 37(12), pages 1469-1483, December.
    7. Morgan, Steven G. & Thomson, Paige A. & Daw, Jamie R. & Friesen, Melissa K., 2013. "Canadian policy makers’ views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers," Health Policy, Elsevier, vol. 112(3), pages 248-254.
    8. Andrew M. Jones (ed.), 2012. "The Elgar Companion to Health Economics, Second Edition," Books, Edward Elgar Publishing, number 14021.
    9. Dunlop, William C.N. & Staufer, Alexandra & Levy, Pierre & Edwards, Guy J., 2018. "Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience," Health Policy, Elsevier, vol. 122(5), pages 528-532.
    10. repec:bla:glopol:v:8:y:2017:i:s2:p:46-59 is not listed on IDEAS
    11. Pauline Chauvin & Jean-Michel Josselin & Denis Heresbach, 2012. "Incremental net benefit and acceptability of alternative health policies: a case study of mass screening for colorectal cancer," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(3), pages 237-250, June.
    12. Reza Mahjoub & Fredrik Ødegaard & Gregory S. Zaric, 2018. "Evaluation of a pharmaceutical risk‐sharing agreement when patients are screened for the probability of success," Health Economics, John Wiley & Sons, Ltd., vol. 27(1), pages 15-25, January.
    13. Bognar, Katalin & Romley, John A. & Bae, Jay P. & Murray, James & Chou, Jacquelyn W. & Lakdawalla, Darius N., 2017. "The role of imperfect surrogate endpoint information in drug approval and reimbursement decisions," Journal of Health Economics, Elsevier, vol. 51(C), pages 1-12.
    14. Ferrario, Alessandra & Kanavos, Panos, 2015. "Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden," Social Science & Medicine, Elsevier, vol. 124(C), pages 39-47.
    15. Elodie Adida, 2021. "Outcome-Based Pricing for New Pharmaceuticals via Rebates," Management Science, INFORMS, vol. 67(2), pages 892-913, February.
    16. Bonny Parkinson & Catherine Sermet & Fiona Clement & Steffan Crausaz & Brian Godman & Sarah Garner & Moni Choudhury & Sallie-Anne Pearson & Rosalie Viney & Ruth Lopert & Adam Elshaug, 2015. "Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review," PharmacoEconomics, Springer, vol. 33(9), pages 905-924, September.
    17. Goldman Dana P. & Lakdawalla Darius N. & Baumgardner James R. & Linthicum Mark T., 2016. "Are Biopharmaceutical Budget Caps Good Public Policy?," The Economists' Voice, De Gruyter, vol. 13(1), pages 27-42, December.
    18. Simon Walker & Mark Sculpher & Karl Claxton & Steve Palmer, 2012. "Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions," Working Papers 077cherp, Centre for Health Economics, University of York.
    19. Pace, Jessica & Ghinea, Narcyz & Kerridge, Ian & Lipworth, Wendy, 2018. "An ethical framework for the creation, governance and evaluation of accelerated access programs," Health Policy, Elsevier, vol. 122(9), pages 984-990.
    20. Paula K Lorgelly, 2018. "The Impact of Brexit on Pharmaceuticals and HTA," PharmacoEconomics - Open, Springer, vol. 2(2), pages 87-91, June.
    21. Kreis, Kristine & Neubauer, Sarah & Klora, Mike & Lange, Ansgar & Zeidler, Jan, 2016. "Status and perspectives of claims data analyses in Germany—A systematic review," Health Policy, Elsevier, vol. 120(2), pages 213-226.

    More about this item

    Keywords

    Colorectal cancer; Palliative care; Cost of care; Health service research; Quality of life; SF-12; I10; I11;
    All these keywords.

    JEL classification:

    • I10 - Health, Education, and Welfare - - Health - - - General
    • I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:14:y:2013:i:4:p:629-638. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.